Ero sivun ”Rituksimabi” versioiden välillä

483 merkkiä lisätty ,  10 vuotta sitten
[katsottu versio][katsottu versio]
Perustuen [[Kliininen tutkimus| kliinisiin tutkimuksiin]],<ref>{{cite journal |author=Maloney DG, Grillo-López AJ, White CA, ''et al.'' |title=IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma |journal=Blood |volume=90 |issue=6 |pages=2188–95 |year=1997 |month=September |pmid=9310469 |doi= |url=}}</ref> rituksimabi sai hyväksynnän USA:n [[FDA]]:lta vuonna 1997.<ref>{{cite journal |author=Scott SD |title=Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma |journal=Cancer Pract |volume=6 |issue=3 |pages=195–7 |year=1998 |pmid=9652253 |doi= 10.1046/j.1523-5394.1998.006003195.x|url=}}</ref> Rituksimabia pidetään hyvänä lääkkeenä muiden lääkkeiden kanssa (yhdistelmähoito) hoidettaessa mm. monia B-solu lymfoomia.<ref>''Harrison's Principles of Internal Medicine'', Longo et al. ''McGraw Hill Medical'' 2011 page 931</ref> In 2010 it was approved by the [[European Commission]] for maintenance treatment after initial treatment of [[follicular lymphoma]].<ref>{{cite news |url= |title=Roche Gets EC Nod for Follicular Lymphoma Maintenance Therapy |date=October 29, 2010 }}</ref>
In Europe, the license is slightly more restrictive: it is licensed for use in combination with MTX in patients with severe active RA who have had an inadequate response to one or more anti-TNF therapy.<ref>{{cite journal
| author = Tak PP, Kalden JR
| title = Advances in rheumatology: new targeted therapeutics
| journal = Arthritis Res Ther
| year = 2011
| volume = 13
| issue = Suppl 1
| pages = S5
| pmid = 21624184
| doi = 10.1186/1478-6354-13-S1-S5
| pmc = 3123966
Rituximab is currently co-marketed by [[Biogen Idec]] and [[Genentech]] in the U.S., by [[Hoffmann–La Roche]] in Canada and the [[European Union]], and by [[Chugai Pharmaceuticals]] and Zenyaku Kogyo in Japan.
1 204